{
  "docId": "019de518-6502-70bc-9a44-c6a9c7f323b5",
  "docSlug": "4230ce80abe7092521a593effe59cbcd",
  "documentTitle": "Oculis | Investor Presentation Deck | 48 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 48,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de518-6502-70bc-9a44-c6a9c7f323b5/15",
  "deckHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5",
  "deckJsonHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5.json",
  "deckAnchorHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.95,
        "x": 0.025,
        "y": 0.12
      },
      "kind": "callout",
      "text": "25.3% of patients gained ≥15 letters at week 6, increasing to 27.4% at week 12",
      "attrs": {},
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "771562bb-b30a-4a2f-9d50-89f120edfa5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.58,
        "w": 0.45,
        "x": 0.05,
        "y": 0.24
      },
      "kind": "chart",
      "text": "≥15-LETTER GAINERS AT WEEK 6*\n%Patients with ≥15 ETDRS letter gain from baseline\nOCS-01 N=100: 25.3%, P = 0.015\nVEHICLE N=48: 9.8%",
      "attrs": {
        "x_axis_label": "OCS-01, VEHICLE",
        "y_axis_label": "%Patients with ≥15 ETDRS letter gain from baseline"
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e0c274b-0bb3-46bf-8cdf-0553a7d46698",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.58,
        "w": 0.45,
        "x": 0.5,
        "y": 0.24
      },
      "kind": "chart",
      "text": "≥15-LETTER GAINERS AT WEEK 12\n%Patients with ≥15 ETDRS letter gain from baseline\nOCS-01 N=100: 27.4%, P = 0.009\nVEHICLE N=48: 7.5%",
      "attrs": {
        "x_axis_label": "OCS-01, VEHICLE",
        "y_axis_label": "%Patients with ≥15 ETDRS letter gain from baseline"
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "720a5939-19fd-4582-977c-106db31cec28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.24,
        "x": 0.72,
        "y": 0.04
      },
      "kind": "image",
      "text": "Oculis Diamond",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86776fa7-f539-4bf2-a99e-608e6817983a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.1,
        "x": 0.05,
        "y": 0.84
      },
      "kind": "paragraph",
      "text": "ITT population",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63512a9d-0269-4478-ac13-3007798f19a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.025,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "* There was no loss of ≥3 lines (>15 ETDRS letters) from baseline to week 6 in either treatment group.\nP-value is based on difference in marginal effects. Imputation rules are applied based on a pattern-mixture model approach.\nETDRS (Early Treatment Diabetic Retinopathy Study); ITT (Intention-to-treat).\nTadayoni R, et al. A 12-week phase 2/3 double-masked, randomized, multicenter study of OCS-01 OPTIREACH® technology topical dexamethasone eye drops in subjects with diabetic macular edema (DME): efficacy and safety findings. Presented at: EURETINA; 2023.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d72d5700-1b13-4df0-936d-3ac8c0c4d641",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.025,
        "y": 0.04
      },
      "kind": "title",
      "text": "5 Key Takeaways From OCS-01 DIAMOND Stage 1",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87347f16-e26e-489f-8ac8-63833695b4e9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}